| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
MAPK13 (p38delta MAPK). MAPK13-IN-1 is a MAPK13 (p38delta) inhibitor that targets the p38delta isoform of the p38 MAPK family, which is involved in cellular responses to stress and inflammation. The compound also inhibits Raf-1 with an IC₅0 of 800.0 nM.
|
|---|---|
| ln Vitro |
In vero E6 cells, MPAK13-IN-1 had an IC50 of 4.63 μM[2].
MAPK13-IN-1 inhibits MAPK13 (p38delta) with an IC₅0 of 620 nM and Raf-1 with an IC₅0 of 800.0 nM. The compound is a selective inhibitor of MAPK13/p38delta, useful for studying the role of p38delta in inflammatory conditions, autoimmune disorders, and certain cancers. |
| ln Vivo |
In vivo, MAPK13-IN-1 would be expected to demonstrate efficacy in models of inflammation, autoimmune disorders, and cancer where p38delta plays a role. By inhibiting p38delta MAPK signaling, the compound modulates inflammatory responses and cellular stress pathways. Efficacy would be assessed in appropriate disease models.
|
| Enzyme Assay |
MAPK13 kinase activity is measured using a kinase assay with recombinant MAPK13 (p38delta) enzyme. The kinase is incubated with ATP and a peptide substrate in the presence of serial dilutions of test compound. Phosphorylation of the substrate is detected by fluorescence, luminescence, or radiometric methods. IC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
Cell viability assay [2]
Cell Types: Vero E6 cells [2]. Tested Concentrations: 0-100 μM. Incubation Duration: Experimental Results: IC50 is 4.63 μM. Cells (e.g., inflammatory cells, cancer cells) are treated with MAPK13-IN-1 at various concentrations. p38delta substrate phosphorylation (e.g., HSP27, ATF2) is assessed by Western blotting using phospho-specific antibodies. Inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta) is measured by ELISA. Cell viability and proliferation are assessed using MTT or CellTiter-Glo assays. |
| Animal Protocol |
Animal models of inflammation (e.g., LPS-induced inflammation, collagen-induced arthritis), autoimmune disorders, or cancer are administered MAPK13-IN-1 via appropriate routes. Inflammatory markers in serum and tissues are measured. Disease progression is monitored by clinical scores, histopathology, and biomarker analysis. Efficacy is determined by disease amelioration.
|
| ADME/Pharmacokinetics |
MAPK13-IN-1 has a molecular weight of 365.43 g/mol and formula C20H23N₅O2. The compound is a solid and transported at room temperature. Standard PK parameters would be determined in rodent studies following IV and PO administration. The compound is formulated in suitable vehicles for in vivo administration.
|
| Toxicity/Toxicokinetics |
Toxicology data for MAPK13-IN-1 are not publicly available. Standard preclinical safety assessment would include cytotoxicity screening, hERG channel inhibition testing, and repeat-dose toxicology studies in rodents. Given the role of p38 MAPK signaling in normal immune responses, potential on-target effects would be evaluated.
|
| References | |
| Additional Infomation |
MAPK13-IN-1 is a research compound for studying p38delta MAPK biology. It is not clinically approved. The compound is useful for investigating the role of p38delta in inflammatory conditions, autoimmune disorders, and certain cancers. MAPK13-IN-1 serves as a tool for validating p38delta as a therapeutic target and for developing novel anti-inflammatory and anticancer therapies.
|
| Molecular Formula |
C20H23N5O2
|
|---|---|
| Molecular Weight |
365.42892
|
| Exact Mass |
365.185
|
| CAS # |
229002-10-2
|
| PubChem CID |
17941505
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
481
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NC1=CC=C(OC2=CC=NC=C2)C=C1)NC3=CC(C(C)(C)C)=NN3C
|
| InChi Key |
MHSLDASSAFCCDO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H23N5O2/c1-20(2,3)17-13-18(25(4)24-17)23-19(26)22-14-5-7-15(8-6-14)27-16-9-11-21-12-10-16/h5-13H,1-4H3,(H2,22,23,26)
|
| Chemical Name |
1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 250 mg/mL (~684.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7365 mL | 13.6825 mL | 27.3650 mL | |
| 5 mM | 0.5473 mL | 2.7365 mL | 5.4730 mL | |
| 10 mM | 0.2737 mL | 1.3683 mL | 2.7365 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
